Jazz Pharmaceuticals (JAZZ) Non-Current Deffered Revenue (2010 - 2022)

Jazz Pharmaceuticals' Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $116000.0 for Q3 2022.

• On a quarterly basis, Non-Current Deffered Revenue fell 88.24% year-over-year to $116000.0 in Q3 2022; TTM through Sep 2022 was $116000.0, a 88.24% decrease from a year earlier, with the FY2021 full-year figure at $463000.0, down 80.0% from the prior year.
• Non-Current Deffered Revenue declined to $116000.0 in Q3 2022 per JAZZ's latest filing, from $231000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $13.6 million in Q1 2018 and bottomed at $116000.0 in Q3 2022.
• The 5-year median for Non-Current Deffered Revenue is $3.6 million (2020), against an average of $4.8 million.
• Across the five-year window, Non-Current Deffered Revenue sank 38.41% in 2019 and tumbled 88.24% in 2022, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $9.6 million in 2018, then slumped by 49.26% to $4.9 million in 2019, then slumped by 52.38% to $2.3 million in 2020, then slumped by 80.0% to $463000.0 in 2021, then slumped by 74.95% to $116000.0 in 2022.
• Per Business Quant, the three latest JAZZ Non-Current Deffered Revenue figures stand at $116000.0 (Q3 2022), $231000.0 (Q2 2022), and $347000.0 (Q1 2022).